• Amplifying Our Shared Mission in the Media: June Media Mentions

    At the Alliance for Clinical Trials in Oncology, our media relations efforts are designed to alert the public about the vital work happening across our network. When we share stories about groundbreaking clinical trials, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. These media features serve a crucial…

  • AFT Study Finds Some Prostate Cancer Drugs Related to More Cognitive Decline

    A new randomized Alliance Foundation Trials (AFT) clinical study found that men with advanced prostate cancer taking the hormone therapy medication darolutamide had less cognitive decline compared to men taking enzalutamide. According to results from the ARACOG (AFT-47) phase II trial, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2026,…

  • At ASCO, Walther Cancer Foundation Honors Charles Loprinzi with Supportive Oncology Award

    At this year’s ASCO Annual Meeting, Charles L. Loprinzi, MD, received the Walther Cancer Foundation Supportive Oncology Award, recognizing his extraordinary contributions to supportive oncology and decades of leadership improving the lives of people with cancer. For Alliance members, Dr. Loprinzi’s impact extends far beyond his scientific achievements. A longtime leader in the Alliance for…

Categories


Alliance Committee


Browse by Year